Daratumumab (DARZALEX): Cornerstone Anti-CD38 Therapy For Multiple Myeloma
- Published: Sep, 2025
- Report ID: GVR-MT-100416
- Format: PDF/Excel databook
- No. of Pages/Datapoints: 120
- Report Coverage: 2024 - 2030
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Application
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Daratumumab (DARZALEX) Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Pricing Analysis
Chapter 4. Daratumumab (DARZALEX) Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2033
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Darzalex (daratumumab) Injection
4.4.1. Darzalex (daratumumab) Injection
4.5. Darzalex Faspro (daratumumab and hyaluronidase-fihj)
4.5.1. Darzalex Faspro (daratumumab and hyaluronidase-fihj)
Chapter 5. Daratumumab (DARZALEX) Market: Application Business Analysis
5.1. Application Market Share, 2024 & 2033
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Newly Diagnosed Multiple Myeloma Patients
5.4.1. Newly Diagnosed Multiple Myeloma Patients
5.5. Relapsed or Refractory Multiple Myeloma Patients
5.5.1. Mantle Cell Lymphoma Market, 2021 - 2033 (USD Million)
5.6. Light Chain (AL) Amyloidosis
5.6.1. Light Chain (AL) Amyloidosis
Chapter 6. Daratumumab (DARZALEX) Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2033
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
6.4. Intravenous (IV)
6.4.1. Intravenous (IV) Market, 2021 - 2033 (USD Million)
6.5. Subcutaneous (SC)
6.5.1. Subcutaneous (SC) Market, 2021 - 2033 (USD Million)
Chapter 7. Daratumumab (DARZALEX) Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
7.4. Hospitals
7.4.1. Hospitals Market, 2021 - 2033 (USD Million)
7.5. Specialty Clinics
7.5.1. Specialty Clinics Market, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. Daratumumab (DARZALEX) Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
8.4.1. North America Daratumumab (DARZALEX) Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
8.5. Europe
8.5.1. Europe Daratumumab (DARZALEX) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Daratumumab (DARZALEX) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America Daratumumab (DARZALEX) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Daratumumab (DARZALEX) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Profile
9.1.1. Janssen Biotech, Inc.
9.1.1.1. Overview
9.1.1.2. Financial Performance
9.1.1.3. Strategic Mapping
9.2. Concurrent Competitive Landscape
9.2.1. Bristol-Myers Squibb Company
9.2.1.1. Overview
9.2.1.2. Financial Performance
9.2.1.3. Disease Benchmarking
9.2.1.4. Strategic Mapping
9.2.2. Genzyme Corporation
9.2.2.1. Overview
9.2.2.2. Financial Performance
9.2.2.3. Disease Benchmarking
9.2.2.4. Strategic Mapping
9.2.3. Juno Therapeutics
9.2.3.1. Overview
9.2.3.2. Financial Performance
9.2.3.3. Disease Benchmarking
9.2.3.4. Strategic Mapping
9.2.4. Millennium Pharmaceuticals
9.2.4.1. Overview
9.2.4.2. Financial Performance
9.2.4.3. Disease Benchmarking
9.2.4.4. Strategic Mapping
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Daratumumab (DARZALEX) market, by region, 2021 - 2033 (USD Million)
Table 4 North America Daratumumab (DARZALEX) market, by Type, 2021 - 2033 (USD Million)
Table 5 North America Daratumumab (DARZALEX) market, by Application, 2021 - 2033 (USD Million)
Table 6 North America Daratumumab (DARZALEX) market, by Route of Administration, 2021 - 2033 (USD Million)
Table 7 North America Daratumumab (DARZALEX) market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 8 Europe Daratumumab (DARZALEX) market, by Type, 2021 - 2033 (USD Million)
Table 9 Europe Daratumumab (DARZALEX) market, by Application, 2021 - 2033 (USD Million)
Table 10 Europe Daratumumab (DARZALEX) market, by Route of Administration, 2021 - 2033 (USD Million)
Table 11 Europe Daratumumab (DARZALEX) market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 12 Asia Pacific Daratumumab (DARZALEX) market, by Type, 2021 - 2033 (USD Million)
Table 13 Asia Pacific Daratumumab (DARZALEX) market, by Application, 2021 - 2033 (USD Million)
Table 14 Asia Pacific Daratumumab (DARZALEX) market, by Route of Administration, 2021 - 2033 (USD Million)
Table 15 Asia Pacific Daratumumab (DARZALEX) market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 16 Latin America Daratumumab (DARZALEX) market, by Type, 2021 - 2033 (USD Million)
Table 17 Latin America Daratumumab (DARZALEX) market, by Application, 2021 - 2033 (USD Million)
Table 18 Latin America Daratumumab (DARZALEX) market, by Route of Administration, 2021 - 2033 (USD Million)
Table 19 Latin America Daratumumab (DARZALEX) market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 20 Middle East & Africa Daratumumab (DARZALEX) market, by Type, 2021 - 2033 (USD Million)
Table 21 Middle East & Africa Daratumumab (DARZALEX) market, by Application, 2021 - 2033 (USD Million)
Table 22 Middle East & Africa Daratumumab (DARZALEX) market, by Route of Administration, 2021 - 2033 (USD Million)
Table 23 Middle East & Africa Daratumumab (DARZALEX) market, by Distribution Channel, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Daratumumab (DARZALEX) market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and disease outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Daratumumab (DARZALEX) market dynamics
Fig. 12 Daratumumab (DARZALEX) market: Porter’s five forces analysis
Fig. 13 Daratumumab (DARZALEX) market: PESTLE analysis
Fig. 14 Type market, 2021 - 2033 (USD Million)
Fig. 15 Darzalex (daratumumab) Injection market, 2021 - 2033 (USD Million)
Fig. 16 Darzalex Faspro (daratumumab and hyaluronidase-fihj) market, 2021 - 2033 (USD Million)
Fig. 17 Application market, 2021 - 2033 (USD Million)
Fig. 18 Newly Diagnosed Multiple Myeloma Patients market, 2021 - 2033 (USD Million)
Fig. 19 Relapsed or Refractory Multiple Myeloma Patients market, 2021 - 2033 (USD Million)
Fig. 20 Light Chain (AL) Amyloidosis market, 2021 - 2033 (USD Million)
Fig. 21 Route of Administration market, 2021 - 2033 (USD Million)
Fig. 22 Intravenous (IV) market, 2021 - 2033 (USD Million)
Fig. 23 Subcutaneous (SC) market, 2021 - 2033 (USD Million)
Fig. 24 Distribution Channel market, 2021 - 2033 (USD Million)
Fig. 25 Hospitals market, 2021 - 2033 (USD Million)
Fig. 26 Specialty Clinics market, 2021 - 2033 (USD Million)
Fig. 27 Others market, 2021 - 2033 (USD Million)
Fig. 28 Daratumumab (DARZALEX) market revenue, by region
Fig. 29 Regional marketplace: Key takeaways
Fig. 30 North America Daratumumab (DARZALEX) market, 2021 - 2033 (USD Million)
Fig. 31 Europe Daratumumab (DARZALEX) market, 2021 - 2033 (USD Million)
Fig. 32 Asia Pacific Daratumumab (DARZALEX) market, 2021 - 2033 (USD Million)
Fig. 33 Latin America Daratumumab (DARZALEX) market, 2021 - 2033 (USD Million)
Fig. 34 MEA Daratumumab (DARZALEX) market, 2021 - 2033 (USD Million)
Fig. 35 Company categorization
Fig. 36 Company market position analysis
Fig. 37 Strategic framework
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.